JP2013508392A - 自己免疫疾患における抗ｃｄ３抗体の投薬 - Google Patents

自己免疫疾患における抗ｃｄ３抗体の投薬 Download PDF

Info

Publication number
JP2013508392A
JP2013508392A JP2012535347A JP2012535347A JP2013508392A JP 2013508392 A JP2013508392 A JP 2013508392A JP 2012535347 A JP2012535347 A JP 2012535347A JP 2012535347 A JP2012535347 A JP 2012535347A JP 2013508392 A JP2013508392 A JP 2013508392A
Authority
JP
Japan
Prior art keywords
antibody
day
fragment
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012535347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508392A5 (OSRAM
Inventor
シャルロット、マッキー
ポール、ポナス
ダグラス、リングラー
マイケル、ローゼンズウィーグ
ルー、バイクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2013508392A publication Critical patent/JP2013508392A/ja
Publication of JP2013508392A5 publication Critical patent/JP2013508392A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012535347A 2009-10-20 2010-10-20 自己免疫疾患における抗ｃｄ３抗体の投薬 Pending JP2013508392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25348209P 2009-10-20 2009-10-20
US61/253,482 2009-10-20
PCT/US2010/053438 WO2011050106A2 (en) 2009-10-20 2010-10-20 Anti-cd3 antibody dosing in autoimmune disease

Publications (2)

Publication Number Publication Date
JP2013508392A true JP2013508392A (ja) 2013-03-07
JP2013508392A5 JP2013508392A5 (OSRAM) 2013-12-05

Family

ID=43900947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535347A Pending JP2013508392A (ja) 2009-10-20 2010-10-20 自己免疫疾患における抗ｃｄ３抗体の投薬

Country Status (5)

Country Link
US (1) US20120269826A1 (OSRAM)
EP (1) EP2490714A4 (OSRAM)
JP (1) JP2013508392A (OSRAM)
CA (1) CA2778334A1 (OSRAM)
WO (1) WO2011050106A2 (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015174439A1 (ja) * 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP2024075713A (ja) * 2016-08-29 2024-06-04 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 抗－ｃｄ３抗体製剤

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305714D0 (en) * 2013-03-28 2013-05-15 Ucl Business Plc Method
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
SG11202111192TA (en) * 2019-04-10 2021-11-29 Macrogenics Inc Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506331A (ja) * 2001-09-26 2005-03-03 アイシス イノヴェイション リミテッド 慢性関節炎の処置
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
WO2007145941A2 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
US20080095766A1 (en) * 2006-06-14 2008-04-24 Macrogenics, Inc. Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity
JP2009507838A (ja) * 2005-09-12 2009-02-26 ノビミューン エスアー 抗ｃｄ３抗体製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506331A (ja) * 2001-09-26 2005-03-03 アイシス イノヴェイション リミテッド 慢性関節炎の処置
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
JP2009507838A (ja) * 2005-09-12 2009-02-26 ノビミューン エスアー 抗ｃｄ３抗体製剤
WO2007145941A2 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
US20080095766A1 (en) * 2006-06-14 2008-04-24 Macrogenics, Inc. Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014045206; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　ｃｌｉｎｉｃａｌ　ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．１１１，　Ｎｏ．３, 2003, ｐ．４０９-４１８ *
JPN6014045209; Ｂｌｏｏｄ Ｖｏｌ．９９，　Ｎｏ．８, 2002, ｐ．２７１２-２７１９ *
JPN6014045212; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　ｒｈｅｕｍａｔｏｌｏｇｙ Ｖｏｌ．２９，　Ｎｏ．９, 2002, ｐ．１９０７-１９１３ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12479929B2 (en) 2010-11-30 2025-11-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
WO2015174439A1 (ja) * 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
JPWO2015174439A1 (ja) * 2014-05-13 2017-04-20 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP2024075713A (ja) * 2016-08-29 2024-06-04 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 抗－ｃｄ３抗体製剤

Also Published As

Publication number Publication date
WO2011050106A2 (en) 2011-04-28
WO2011050106A3 (en) 2011-08-04
EP2490714A4 (en) 2013-11-13
US20120269826A1 (en) 2012-10-25
EP2490714A2 (en) 2012-08-29
CA2778334A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP2013508392A (ja) 自己免疫疾患における抗ｃｄ３抗体の投薬
AU2019246821B2 (en) Anti-cd40 antibodies and uses thereof
TWI600433B (zh) 以Dll4拮抗劑治療自體免疫疾病之方法
US20130095121A1 (en) Methods of treating patients with immune-related diseases
MX2008011785A (es) Metodos de tratamiento de lupus utilizando anticuerpos cd4.
TW201943731A (zh) 用於預防移植物排斥之抗cd40抗體
TW202311293A (zh) 免疫療法之組合及其用途
JP2022116272A (ja) Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
JP2021525769A (ja) Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与
JP2013508391A (ja) 体重増加を予防するために抗ｃｄ３抗体を使用する方法
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
WO2025128263A1 (en) Anti-pd-1 monoclonal antibody and methods of preparation thereof
TW202417487A (zh) 治療在ｔ細胞受體內帶有ｔｒｂｖ９節段的ｔ淋巴細胞所介導的疾病或病症之方法
HK40016286A (en) Anti-cd40 antibodies and uses thereof
HK40016286B (en) Anti-cd40 antibodies and uses thereof
HK1193347A (en) Anti-cd40 antibodies and uses thereof
HK1193347B (en) Anti-cd40 antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150407